Displaying drugs 15551 - 15575 of 16219 in total
AK-OTOF
Investigational
BRG01
BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.
Investigational
BNT111
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
Investigational
CT103A
CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
Investigational
CT120
CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.
Investigational
VCN-01
VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20.
Investigational
GX-G8
GX-G8 is a long-acting glucagon-like peptide 2 (GLP-2) being investigated for the treatment of short bowel syndrome.
Investigational
Ilixadencel
Investigational
GRObeta
Investigational
Osemitamab
Investigational
Tagitanlimab
Investigational
TSHA-104
Investigational
XMT-2056
XMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.
Investigational
AP103
AP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Investigational
TLR-AD1
Investigational
Human autologous bone marrow derived osteoblastic cells
Investigational
Human glial progenitor cells
Investigational
HM15912
HM15912 is a human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment.
Investigational
LX2006
Investigational
SP-101
Investigational
OT-004
Investigational
AO-176
Investigational
Ulenistamab
Investigational
CM-101
Investigational
Displaying drugs 15551 - 15575 of 16219 in total